Skip to main content

Table 3 Clinical results at 5 years

From: Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

  Sirolimus- and probucol-eluting stent (n = 575) Zotarolimus-eluting stent (n = 295) Hazard ratio [95 % CI] P value
Cardiac death, target vessel-related myocardial infarction or target lesion revascularization 178 (32.9) 91 (33.4) 0.98 [0.76–1.26] 0.88
Cardiac death or target vessel-related myocardial infarction 101 (19.1) 54 (20.1) 0.94 [0.67–1.30] 0.70
Cardiac death 81 (15.6) 44 (16.7) 0.92 [0.63–1.32] 0.64
Target vessel-related myocardial infarction 26 (4.6) 18 (6.6) 0.73 [0.40–1.34] 0.31
Target lesion revascularization 100 (18.6) 50 (18.8) 1.00 [0.72–1.41] 0.98
All-cause death 133 (24.4) 79 (27.8) 0.84 [0.63–1.11] 0.21
Any myocardial infarction 37 (6.5) 21 (7.6) 0.90 [0.53–1.54] 0.70
Any revascularization 234 (43.4) 124 (46.9) 0.92 [0.74–1.15] 0.48
Target vessel revascularization 144 (26.8) 70 (26.2) 0.82 [0.78–1.37] 0.82
Definite or probable stent thrombosis 14 (2.5) 7 (2.6) 1.02 [0.41–2.52] 0.97
Definite stent thrombosis 7 (1.2) 4 (1.6) 0.89 [0.26–3.04] 0.85
Probable stent thrombosis 7 (1.2) 3 (1.0) 1.19 [0.31–4.60] 0.80
  1. Data shown as n (%) or hazard ratio [95 % CI]
  2. Rates are estimated by Kaplan–Meier method; hazard ratios and p values were calculated by Cox’s proportional hazard methods
  3. CI confidence intervals